QURE241115P6000
- 0.35
- 0.000.00%
uniQure NV Newsroom
TD Cowen Maintains UniQure NV(QURE.US) With Buy Rating
William Blair Maintains UniQure NV(QURE.US) With Buy Rating
uniQure NV | 10-Q: Quarterly report
UniQure GAAP EPS of -$0.91 Beats by $0.03, Revenue of $2.29M Misses by $4.77M
UniQure: Cash Runway Through End of 2027 >QURE
Earnings Flash (QURE) UNIQURE Reports Q3 Revenue $2.3M
UniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
UniQure 3Q Loss/Shr 91c >QURE
UniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
Raymond James Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $20
UniQure Price Target Announced at $20.00/Share by Raymond James
UniQure (NASDAQ:QURE) Shareholders Are up 28% This Past Week, but Still in the Red Over the Last Five Years
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
FDA Grants Orphan Drug Status to UniQure's AMT-191, Aiming to Treat Fabry Disease
UniQure Biopharma Granted Orphan Drug Designation For Its 'Adeno-associated Viral Vector Serotype 5 Encoding Human Alpha-galactosidase A' For The Treatment Of Fabry Disease
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $25
H.C. Wainwright analyst Patrick Trucchio maintains $uniQure NV(QURE.US)$ with a buy rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 29.0%
HC Wainwright & Co. Reiterates Buy on UniQure, Maintains $25 Price Target
UniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
UniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know
UniQure to Cut 65% of Workforce, or 300 Jobs, in Major Restructuring